Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6165 posts found.

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023 Medical Communications Devices, FDA, Vivos Therapeutics, sleep apnea

Vivos Therapeutics has announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for the …
News

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023 Medical Communications COPD, Cardiology, Dupixent, Sanofi, clinical trial

Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for Dupixent as a treatment for …
News
testalize-me-0je8ynv4mis-unsplash

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023 Medical Communications Blenrep, GSK, Oncology, clinical trial, multiple myeloma

GSK has announced positive results from a planned interim efficacy analysis of the phase 3 DREAMM-7 head-to-head trial which assessed …
News

Landos Biophama shares results from phase 1b trial for ulcerative colitis treatment

November 23, 2023 Medical Communications Gastrointestinal tract, Landos Biopharma, clinical trial, ulcerative colitis

Landos Biopharma has announced that it has shared safety, tolerability, pharmacokinetics and clinical efficacy results for the NX-13 phase 1b …
News

GSK’s low carbon inhaler, Ventolin, progresses to phase 3 trials 

November 21, 2023 Medical Communications Asthma & COPD, GSK, Ventolin, asthma, carbon-neutral

GSK has announced that in 2024 it intends to start phase 3 trials of a low carbon version of its …
News

Almirall gains EC approval of Ebglyss for moderate-to-severe atopic dermatitis

November 20, 2023 Medical Communications Almirall, Dermatology, Ebglyss, European Commission, atopic dermatitis

Almirall has announced that the European Commission (EC) has approved Ebglyss (lebrikizumab) for the treatment of adult and adolescent patients …
News

FDA approves AstraZeneca’s Truqap plus Faslodex for breast cancer treatment

November 17, 2023 Medical Communications AstraZeneca, FDA, Faslodex, Oncology, breast cancer

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Truqap (capivasertib) in combination with Faslodex (fullvestrant) …
News

FDA approves Merck’s Keytruda for gastric cancer treatment

November 17, 2023 Medical Communications FDA, MSD, Merck, Oncology, gastric cancer, keytruda

Merck, known as MSD outside of the US, has announced that the US Food and Drug Administration (FDA) has approved …
News

FDA approves BMS’s Augtyro for lung cancer treatment

November 16, 2023 Medical Communications FDA, Oncology, bristol myers squibb, lung cancer

Bristol Myers Squibb has announced that the US Food and Drug Administration (FDA) has approved Augtyro (repotrectinib) for the treatment …
News

Kesin Pharma’s Likmez approved by FDA

November 15, 2023 Medical Communications Kesin Pharma, Likmez, Pharmacy, Saptalis Pharmaceuticals, antibiotic

Kesin Pharma has announced that the US Food and Drug Administration (FDA) has approved Likmez (metronidazole) oral suspension, 500mg/5mL, for …
News

Alvotech and JAMP Pharma’s Jamteki gains marketing authorisation from Health Canada

November 15, 2023 Medical Communications Alvotech, Health Canada, JAMP Pharma, Pharmacy, biosimilar

Alvotech and JAMP Pharma have announced that Health Canada has granted JAMP Pharma marketing authorisation for AVT04, a biosimilar to …
News

Health Canada approves Ipsen and Medision Pharma’s Bylvay for pruritus treatment

November 14, 2023 Medical Communications Health Canada, Medision Pharma, Rare Diseases, ipsen, pruritis

Ipsen and Medision Pharma have announced that Health Canada has approved Bylvay (odevixibat) for the treatment of pruritis in patients …
News
testalize-me-0je8ynv4mis-unsplash

GSK gains positive CHMP opinion for momelotinib for myelofibrosis treatment

November 13, 2023 Medical Communications CHMP, GSK, Haematology, anaemia, momelotinib, myelofibrosis

GSK has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has …
News

Daiichi Sankyo’s Vanflyta approved by EC for acute myeloid leukaemia treatment

November 10, 2023 Medical Communications Daiichi Sankyo, EC, EU, Oncology, Vanflyta, acute myeloid leukaemia

Daiichi Sankyo has announced that Vanflyta (quizartinib) has been approved in the EU for combination use with standard cytarabine and …
News

Eli Lilly’s Zepbound approved by FDA for chronic weight management

November 9, 2023 Medical Communications Eli Lilly, FDA, Obesity, Zepbound, weight loss, weight management

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Zepbound (tirzepatide) injection for chronic weight …
News

Latest content

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023

FDA grants breakthrough device designation to Inflammatix’s TriVerity Acute Infection and Sepsis Test System

November 29, 2023

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023